534 related articles for article (PubMed ID: 34105780)
21. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
22. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
Younossi ZM; Noureddin M; Bernstein D; Kwo P; Russo M; Shiffman ML; Younes Z; Abdelmalek M
Am J Gastroenterol; 2021 Feb; 116(2):254-262. PubMed ID: 33284184
[TBL] [Abstract][Full Text] [Related]
23. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
Okanoue T; Ebise H; Kai T; Mizuno M; Shima T; Ichihara J; Aoki M
J Gastroenterol; 2018 Jan; 53(1):129-139. PubMed ID: 28589339
[TBL] [Abstract][Full Text] [Related]
24. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
[TBL] [Abstract][Full Text] [Related]
25. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
[TBL] [Abstract][Full Text] [Related]
26. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
Lubner MG; Graffy PM; Said A; Watson R; Zea R; Malecki KM; Pickhardt PJ
AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
[No Abstract] [Full Text] [Related]
27. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
28. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
[TBL] [Abstract][Full Text] [Related]
30. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.
Kruger FC; Daniels CR; Kidd M; Swart G; Brundyn K; van Rensburg C; Kotze M
S Afr Med J; 2011 Jun; 101(7):477-80. PubMed ID: 21920102
[TBL] [Abstract][Full Text] [Related]
31. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease.
Stefano JT; Guedes LV; de Souza AAA; Vanni DS; Alves VAF; Carrilho FJ; Largura A; Arrese M; Oliveira CP
Ann Hepatol; 2021; 20():100253. PubMed ID: 32949785
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
[TBL] [Abstract][Full Text] [Related]
35. Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease.
Marella HK; Reddy YK; Jiang Y; Ganguli S; Podila PSB; Snell PD; Kovalic AJ; Cholankeril G; Singal AK; Nair S; Maliakkal B; Satapathy SK
Clin Transl Gastroenterol; 2020 Apr; 11(4):e00165. PubMed ID: 32352687
[TBL] [Abstract][Full Text] [Related]
36. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.
Kessoku T; Ogawa Y; Yoneda M; Imajo K; Sumida Y; Eguchi Y; Fujii H; Hyogo H; Ono M; Suzuki Y; Kawaguchi T; Chayama K; Tanaka S; Fujimoto K; Anzai K; Saibara T; Sata M; Itoh Y; Nakajima A; Okanoue T;
World J Gastroenterol; 2014 Aug; 20(29):10108-14. PubMed ID: 25110437
[TBL] [Abstract][Full Text] [Related]
37. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
[TBL] [Abstract][Full Text] [Related]
38. Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
Kobayashi N; Kumada T; Toyoda H; Tada T; Ito T; Kage M; Okanoue T; Kudo M
Dig Dis; 2017; 35(6):521-530. PubMed ID: 29040984
[TBL] [Abstract][Full Text] [Related]
39. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
Younossi ZM; Page S; Rafiq N; Birerdinc A; Stepanova M; Hossain N; Afendy A; Younoszai Z; Goodman Z; Baranova A
Obes Surg; 2011 Apr; 21(4):431-9. PubMed ID: 20532833
[TBL] [Abstract][Full Text] [Related]
40. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
Caussy C; Ajmera VH; Puri P; Hsu CL; Bassirian S; Mgdsyan M; Singh S; Faulkner C; Valasek MA; Rizo E; Richards L; Brenner DA; Sirlin CB; Sanyal AJ; Loomba R
Gut; 2019 Oct; 68(10):1884-1892. PubMed ID: 30567742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
